Humacyte, Inc. (HUMA)
| Market Cap | 153.93M -45.2% |
| Revenue (ttm) | 2.12M +159.3% |
| Net Income | -96.67M |
| EPS | -0.50 |
| Shares Out | 277.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,800,826 |
| Open | 0.5599 |
| Previous Close | 0.5657 |
| Day's Range | 0.5430 - 0.5693 |
| 52-Week Range | 0.5261 - 2.5500 |
| Beta | 2.45 |
| Analysts | Buy |
| Price Target | 1.85 (+233.88%) |
| Est. Earnings | Nov 11, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price target is $1.85, which is an increase of 233.88% from the latest price.
News
Humacyte Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Symvess, an FDA-approved bioengineered vessel, is expanding from trauma to dialysis and cardiovascular markets, with a supplemental BLA for dialysis access planned for November 2026 and CABG trials starting in 2026. Commercial efforts are being rebuilt, and financial runway extends into late 2027.
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte announces FDA extension of expiration dating period for Symvess
Humacyte (HUMA) announced that the FDA has authorized an extension of the expiration dating period for Symvess from 18 months to 36 months when stored refrigerated at 2 degrees C…
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all establish...
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...
Humacyte confirms plans for ATEV supplemental biologic license application
Humacyte (HUMA) announced that recent discussions with the FDA confirm the company’s plans and expectations for filing a supplemental biologic license application, or BLA, with the FDA for the acellul...
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
Humacyte publishes V007 results in The Lancet Digital Health
Humacyte (HUMA) announced the publication of one-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel in arteriovenous access for hemodialysis patients in The La...
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
Humacyte reports Q2 EPS (16c), consensus (10c)
Reports Q2 revenue $406,000, consensus $1.11M. “Our second quarter and recent weeks have been a transformative period for Humacyte (HUMA) and our pipeline expansion, led by the presentation of breakth...
Humacyte price target lowered to $1 from $2 at Benchmark
Benchmark lowered the firm’s price target on Humacyte (HUMA) to $1 from $2 and keeps a Speculative Buy rating on the shares. tThe near-term adoption rate is difficult to predict…
Humacyte Earnings Call Transcript: Q2 2026
Q2 2026 saw transformative clinical and commercial progress, with strong trial results for ATEV, increased SYMVESS adoption, and a rebuilt commercial team. Financials showed higher sales but continued net losses, while regulatory filings and new studies are on track for late 2026 and 2027.
Humacyte Earnings release: Q2 2026
Humacyte released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Humacyte Quarterly report: Q2 2026
Humacyte has published its Q2 2026 quarterly earnings report on August 12, 2026.
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with ...
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte announces FDA acceptance of CTEV IND application
Humacyte (HUMA) announced that the FDA has accepted its investigational new drug, or IND, application for a first-in-human clinical study of the coronary tissue engineered vessel in coronary artery by...
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at mul...
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North ...
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
TD Cowen lowered the firm’s price target on Humacyte (HUMA) to $1.25 from $1.50 and keeps a Buy rating on the shares. The firm said they are encouraged by the…
Humacyte Slides: Corporate presentation
Humacyte has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Humacyte Transcript: Study result
The V012 phase III interim analysis showed ATEV significantly increased catheter-free days and reduced infections versus AVF in women on hemodialysis, with a favorable safety profile and superior maturation rates. These results support a planned FDA filing for use in high-risk patients.
Humacyte Press release: Study result
Humacyte issued a press release on June 15, 2026, disclosing material business information to investors.
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of t...